Strides Acquires 18 ANDAs From Pharmaceutics
Deal Also Includes Exclusive Rights To Levothyroxine Candidate
Strides has acquired 18 ANDAs from Pharmaceutics International, as well as exclusive marketing rights to a levothyroxine sodium candidate. Through this agreement, the Indian company plans to expand its niche offerings.
You may also be interested in...
Strides' newly-appointed CEO, R Ananthanarayanan, sees no reason to change course as the firm's current strategy continues to yield positive results. The company posted a 29% increase in third-quarter revenues on the back of 62% growth in the US.
Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.
Amgen has filed a US patent-infringement lawsuit against Pfizer’s Hospira over its biosimilar pegfilgrastim rival to Neulasta.